Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsYeast hybrid systems, especially yeast two-hybrid (Y2H), have been recognized as one of the most standardized in vivo approaches for protein-protein and protein-nucleic acid interaction screening and detection. Experienced in providing protein-protein interaction assay services, Creative Biolabs has developed and launched drug-target interaction services based on our perfect Y2H technology platform to boost novel drug discovery.
Almost all drugs, no matter small molecule compounds or biological macromolecules, achieve their therapeutic effects through binding to the specific target proteins and thus affecting the biological activities or functions of the targets. The identification of drug-target interactions is a crucial factor in the drug discovery process, which not only contributes to the explication of the pathomechanism of diseases and mechanisms of drugs but also aids to maximize the therapeutic effect while reducing adverse side effects.
Drug-target interaction screening is a time-consuming, laborious, and complex process, which is roughly divided into computational prediction and experimental validation. The computational/in silico technique is an important, effective, and time & cost-saving approach to predict drug-target interactions on a large scale. Drug-target interaction prediction by in silico technique then should be performed and validated by biological assays and animal experiments. Currently, a variety of in vivo and in vitro experiments have been developed to screen and identify drug-target interactions, such as protein microarray, pull-down assay, affinity chromatography, yeast hybrid assays, and so forth.
In 1989, yeast two-hybrid (Y2H) system has been introduced to screen and detect protein-protein and protein-nucleic acid interactions in the yeast Saccharomyces cerevisiae. It is based on the principle that the Gal4 transcription factor in the yeast Saccharomyces cerevisiae is composed of two functional domains, one is the DNA-binding domain mediating DNA binding and the other is the activation domain responsible for transcription activation. The two functional domains of the Gal4 transcriptional activator can not activate the transcription when they are separated. Only when the two separated passages are relatively close in space, the complete GAL4 transcription factor activity can be represented, and the downstream promoter of the upstream activation sequence can be activated, so that the gene downstream of the promoter can be transcribed. Over these decades, Y2H has been extensively applied for protein interaction screening and identification all through the world, and different Y2H variant methods also have been developed.
Fig.1 Y2H methods and their applications to detect protein-protein or protein-small-molecule interactions. (Hamdi, 2012)
In order to the excellent performance in the detection of protein-protein and protein-nucleic acid interactions, Y2H also is a valuable tool for chemical drug-target interaction identification. In Y2H-based drug-target interaction screening or identification, a tool protein is introduced to be fused with the DNA-binding domain and tagged chemical compounds or drugs of interest then bind to the tool protein. The whole complex is used as a bait to screen the RNA, cells, or tissues prepared library on the activation domain. Also, this system can be used for the validation of the interaction of the drug with the specified protein/target one by one.
Fig.2 Drug-target interaction identification or screening based on the Y2H system. (Creative Biolabs)
Creative Biolabs has completed plenty of protein-protein interaction screening or validation based on yeast hybrid systems, accumulating abundant expertise and experience in protein-protein interaction identifications. Added by rich experience and the perfect technology platform, our seasoned scientists offer one-stop or tailored Y2H-based drug-target interaction identification services to global clients.
Just feel free to contact us and communicate with us about your questions, our experienced technicians will give you the most tailored solutions to you.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
